NCT02047175View on ClinicalTrials.gov

CKD-346 DDI Study(Telmisartan/S-Amlodipine, Rosuvastatin)

PHASE1CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

March 31, 2014

Study Completion Date

March 31, 2014

Conditions
HypertensionHyperlipidemia
Interventions
DRUG

Telmisartan/S-Amlodipine

Telmisartan/S-Amlodipine 40/2.5mg 2T PO, QD for 9days

DRUG

Rosuvastatin

Rosuvastatin 20mg 1T PO, QD for 5days

DRUG

Telmisartan/S-Amlodipine + Rosuvastatin

Telmisartan/S-Amlodipine 40/2.5mg 2T + Rosuvastatin 20mg 1T PO, QD for 5days

DRUG

Telmisartan/S-Amlodipine + Rosuvastatin

Telmisartan/S-Amlodipine 40/2.5mg 2T + Rosuvastatin 20mg 1T PO, QD for 9days

Trial Locations (1)

Unknown

The catholic university of Korea, seoul ST.Mary's hospital, Seoul

Sponsors
All Listed Sponsors
lead

Chong Kun Dang Pharmaceutical

INDUSTRY

NCT02047175 - CKD-346 DDI Study(Telmisartan/S-Amlodipine, Rosuvastatin) | Biotech Hunter | Biotech Hunter